Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Melperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.67 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melperone SCHEMBL146287 | 0.99 | KMT2A (1.00) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL30658979 | 0.88 | MEN1 (0.76) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| SCHEMBL20254428 | 0.86 | MEN1 (0.78) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| SCHEMBL13913702 | 0.86 | KMT2A (0.78) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| Lenperone SCHEMBL11453463 | 0.85 | MEN1 (0.72) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| SCHEMBL11415059 | 0.85 | MEN1 (0.76) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| SCHEMBL4491395 | 0.85 | KMT2A (0.76) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| SCHEMBL22778808 | 0.85 | HTR1A (0.76) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL16986196 | 0.85 | TSHR (1.00) | KMT2AMEN1CHRM2HTR1AADRA2A | |
| Lenperone SCHEMBL121686 | 0.84 | MEN1 (0.74) | KMT2AMEN1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-20180318298-A1 | Method of Treating Obesity | MCMASTER UNIVERSITY (CA) | 2018-11-08 | — | — | US | claimed |
| US-20150290181-A1 | COMBINATION OF EFFECTIVE SUBSTANCES CAUSING SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF | VIVOZONE, INC. (KR) | 2015-10-15 | — | — | US | claimed |
| EP-2727473-A2 | COMBINATION OF EFFECTIVE SUBSTANCES CAUSING SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF | Vivozon, Inc. (KR) | 2014-05-07 | — | — | EP | claimed |
| WO-2010077927-A1 | COMPOSITIONS COMPRISING MELPERONE AND CONTROLLED-RELEASE DOSAGE FORMS | EURAND, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| WO-2010077916-A1 | COMPOSITIONS COMPRISING MELPERONE | EURAND, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100151015-A1 | Compositions Comprising Melperone and Controlled-Release Dosage Forms | APTALIS PHARMATECH, INC. | 2010-06-17 | — | — | US | claimed |
| US-20100151021-A1 | Compositions Comprising Melperone | APTALIS PHARMATECH, INC. | 2010-06-17 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-4344952-A | Method of treating diarrhoea with gamma-piperidino-butyrophenones | AB FERROSAN (SE) | 1982-08-17 | — | — | US | claimed |
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | disclosed |
| EP-2646003-B1 | RAPIDLY DISPERSING GRANULES, ORALLY DISINTEGRATING TABLETS AND METHODS | ADARE PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2506835-B1 | COMPRESSIBLE-COATED PHARMACEUTICAL COMPOSITIONS AND TABLETS AND METHODS OF MANUFACTURE | ADARE PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-5221679-A | Useful for those patient who had experienced inadequate clinical response or adverse effects from, clozapine and or neuroleptic drugs | CASE WESTERN RESERVE UNIVERSITY (US) | 1993-06-22 | — | — | US | disclosed |
| EP-0111144-B1 | SUSTAINED RELEASE SOLID DOSAGE FORMS HAVING NON-UNIFORM DISTRIBUTION OF ACTIVE INGREDIENT | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0111144-A1 | Sustained release solid dosage forms having non-uniform distribution of active ingredient | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4344952-A | Method of treating diarrhoea with gamma-piperidino-butyrophenones | AB FERROSAN (SE) | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318298-A1 | Method of Treating Obesity | GPR119, HTR2A, GIPR | CHRM2 370/4885HTR1A 7/4885ADRA2A 45/4885 |
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | CHRM2 370/4885HTR1A 7/4885ADRA2A 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.